EDP Sciences logo
Authentification abonné
Rechercher
Menu
Accueil Tous les numéros Volume 41 / Numéro 5 (Mai 2025) Med Sci (Paris), 41 5 (2025) 416-424 Références
Open Access
Numéro
Med Sci (Paris)
Volume 41, Numéro 5, Mai 2025
Enjeux et objectifs de la psychiatrie de précision
Page(s) 416 - 424
Section La psychiatrie de précision (PEPR PROPSY) : hypothèses et outils
DOI https://doi.org/10.1051/medsci/2025072
Publié en ligne 26 mai 2025
  1. Perlman RL, Govindaraju DR, Garrod AE. The father of precision medicine. Genet Med 2016 ; 18 : 1088–9. [CrossRef] [PubMed] [Google Scholar]
  2. Giroux E, Gansel Y, Basbous L, et al. Oncologie et psychiatrie : pour une relation réciproque féconde. Med Sci (Paris) 2022 ; 38 : 381–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  3. Fernandes B, Williams L, Steiner J, et al. The new field of precision psychiatry. BMC Med 2017 ; 15 : 80. [CrossRef] [PubMed] [Google Scholar]
  4. Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001 ; 69 : 89–95. [CrossRef] [PubMed] [Google Scholar]
  5. Demazeux S, Pidoux V. Le projet RDoC : la classification psychiatrique de demain ? Med Sci (Paris) 2015 ; 31 : 792–6. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  6. Williams L, Carpenter W, Carretta C, et al. Precision psychiatry and research domain criteria: implications for clinical trials and future practice. CNS Spectr 2024 ; 29 : 26–39. [CrossRef] [PubMed] [Google Scholar]
  7. Cuthbert Bruce, Thomas Insel. Toward the future of psychiatric diagnosis: the seven pillars of RDoC ». BMC Med 2013 ; 11 : 126. [CrossRef] [PubMed] [Google Scholar]
  8. Sanislow Charles, Daniel Pine, Kevin Quinn, et al. Developing constructs for psychopathology research: research domain criteria ». J Abnorm Psychol 2010 ; 119 : 631–9. [CrossRef] [PubMed] [Google Scholar]
  9. Sensorimotor Domain Added to the RDoC Framework - National Institute of Mental Health (NIMH). 2019. https://www.nimh.nih.gov/news/science-news/2019/sensorimotor-domain-added-to-the-rdoc-framework [Google Scholar]
  10. Cuthbert B. Le cadre de travail des RDoC : faciliter la transition de la CIM et du DSM vers des approches dimensionnelles qui intègrent les neurosciences et la psychopathologie. Ann Med-Psychol 2021 ; 179 : 75–85. [Google Scholar]
  11. RDoC Matrix. National Institute of Mental Health (NIMH). s.d. Consulté le 27 décembre 2024. https://www.nimh.nih.gov/research/research-funded-by-nimh/rdoc/constructs/rdoc-matrix [Google Scholar]
  12. Hakak-Zargar B, Tamrakar A, Voth T, et al. The utility of research domain criteria in diagnosis and management of dual disorders: a mini-review. Front Psychiatry 2022 ; 13 : 805163. [CrossRef] [PubMed] [Google Scholar]
  13. Leucht S, Hierl S, Kissling W, et al. Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses. Br J Psychiatry 2012 ; 200 : 97–106. [CrossRef] [PubMed] [Google Scholar]
  14. Siskind D, Orr S, Sinha S, et al. Rates of treatment-resistant schizophrenia from first-episode cohorts: systematic review and meta-analysis. Br J Psychiatry 2022 ; 220 : 115–20. [CrossRef] [PubMed] [Google Scholar]
  15. McIntyre R, Alsuwaidan M, Bernhard T, et al. Treatment resistant depression: definition, prevalence, detection, management, and investigational interventions. World Psychiatry 2023 ; 22 : 394–412. [CrossRef] [PubMed] [Google Scholar]
  16. Lenze E, Nicol G, Barbour D, et al. Precision clinical trials: a framework for getting to precision medicine for neurobehavioural disorders. J Psychiatry Neurosci 2021 ; 46 : E97–110. [CrossRef] [PubMed] [Google Scholar]
  17. Salazar de Pablo G, Studerus E, Vaquerizo-Serrano J, et al. Implementing precision psychiatry: a systematic review of individualized prediction models for clinical practice. Schizophr Bull 2021 ; 47 : 284–97. [CrossRef] [PubMed] [Google Scholar]
  18. Mcgorry P. Stage-specific treatment of psychotic disorders. Psychiatric Times 2020 ; 37 : 6. [Google Scholar]
  19. Di Lisi A, Pupo S, Menchetti M, et al. Antipsychotic treatment in people at clinical high risk for psychosis. J Clin Psychopharmacol 2024 ; 44 : 502–8. [CrossRef] [PubMed] [Google Scholar]
  20. Delaby C, Lehmann S. Vers un diagnostic biologique sanguin de la maladie d’Alzheimer ? Med Sci (Paris) 2024 ; 40 : 351–60. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  21. Leblond C, Rolland T, Barthome E, et al. A genetic bridge between medicine and neurodiversity for autism. Annu Rev Genet 2024 ; 58 : 487–512. [CrossRef] [PubMed] [Google Scholar]
  22. Gilgenkrantz H. La pléiotropie antagoniste et le paradoxe de la sénescence. Med Sci (Paris) 2025 ; 41 : 68. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  23. Chaumette B, Ferrafiat V, Ambalavanan A, et al. Missense variants in ATP1A3 and FXYD gene family are associated with childhood-onset schizophrenia. Mol Psychiatry 2020 ; 25 : 821–30. [CrossRef] [PubMed] [Google Scholar]
  24. Balestrini S, Mikati M, Álvarez-García-Rovés R, et al. Cardiac phenotype in ATP1A3-related syndromes: a multicenter cohort study. Neurology 2020 ; 95 : e2866–79. [CrossRef] [PubMed] [Google Scholar]
  25. Louveau C, Ellul P, Iftimovici A, et al. Neurodevelopmental disorders (NDD) without boundaries: research and interventions beyond classifications. J Neural Transm (Vienna) 2023 ; 130 : 473–9. [CrossRef] [PubMed] [Google Scholar]
  26. Tamminga CA, Pearlson G, Keshavan M, et al. Bipolar and schizophrenia network for intermediate phenotypes: outcomes across the psychosis continuum. Schizophr Bull 2014 ; 40 : S131–7. [CrossRef] [PubMed] [Google Scholar]
  27. Dyar B, Meaddough E, Sarasua S, et al. Genetic findings as the potential basis of personalized pharmacotherapy in phelan-McDermid syndrome. Genes 2021 ; 12 : 1192. [CrossRef] [PubMed] [Google Scholar]
  28. Louveau C, Turtuluci MC, Consoli A, et al. Prader-Willi syndrome: symptoms and topiramate response in light of genetics. Front Neurosci 2023 ; 17 : 1126970. [CrossRef] [PubMed] [Google Scholar]
  29. Berry-Kravis E, Lindemann L, Jønch A, et al. Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome. Nat Rev Drug Discov 2018 ; 17 : 280–99. [CrossRef] [PubMed] [Google Scholar]
  30. Keary C, McDougle C. Current and emerging treatment options for Angelman syndrome. Expert Rev Neurother 2023 ; 23 : 835–44. [CrossRef] [PubMed] [Google Scholar]
  31. Pollak T, Lennox B, Müller S, et al. Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. Lancet Psychiatry 2020 ; 7 : 93–108. [CrossRef] [PubMed] [Google Scholar]
  32. Koutsouleris N, Buciuman MO, Vetter CS, et al. Distinct multimodal biological and functional profiles of symptom-based subgroups in recent-onset psychosis. Research Square 2024 ; mars, rs.3.rs-3949072 (preprint). [PubMed] [Google Scholar]
  33. Lema Y, Gamo N, Yang K, Ishizuka K. Trait and state biomarkers for psychiatric disorders: importance of infrastructure to bridge the gap between basic and clinical research and industry. Psychiatry Clin Neurosci 2018 ; 72 : 482–9. [CrossRef] [PubMed] [Google Scholar]
  34. Passos IC, Ballester B, Rabelo-da-Ponte FD, et al. Precision psychiatry: the future is now. Can J Psychiatry 2022 ; 67 : 21–5. [CrossRef] [PubMed] [Google Scholar]
  35. Parimbelli E, Sacchi M, Bellazzi R. Patient similarity for precision medicine: a systematic review. J Biomed Inform 2018 ; 83 : 87–96. [CrossRef] [PubMed] [Google Scholar]
  36. Koval I, Bône A, Louis M, et al. AD course map charts Alzheimer’s disease progression. Sci Rep 2021 ; 11 : 8020. [CrossRef] [PubMed] [Google Scholar]
  37. Marquand A, Rezek I, Buitelaar J, al. Understanding heterogeneity in clinical cohorts using normative models: beyond case-control studies. Biol Psychiatry 2016 ; 80 : 552–61. [CrossRef] [PubMed] [Google Scholar]
  38. Dumas M, Fay AF, Charpentier E, et al. Le jumeau numérique en santé : état des lieux et perspectives d’application à l’hôpital. Med Sci (Paris) 2023 ; 39 : 953–57. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  39. Spitzer M, Dattner I, Zilcha-Mano S. Digital twins and the future of precision mental health. Front Psychiatry 2023 ; 14 : 1082598. [CrossRef] [PubMed] [Google Scholar]
  40. Wickramasinghe N, Ulapane N, Sloane E, et al. Digital twins for more precise and personalized treatment. Stud Health Technol Inform 2024 ; 310 : 229–33. [PubMed] [Google Scholar]
  41. Verstuyft C, Dewolf D, Blin O, et al. How to facilitate the wider use of pharmacogenetic tests? Therapie 2024 ; décembre, S0040-5957(24)00215-4. [Google Scholar]
  42. Lewis C, Vassos E. Polygenic risk scores: from research tools to clinical instruments. Genome Med 2020 ; 12 : 44. [CrossRef] [PubMed] [Google Scholar]
  43. PROPSY - Programme-Projet en Psychiatrie de Précision. s. d. Agence Nationale de la Recherche. Consulté le 27 décembre 2024. https://anr.fr/en/france-2030/programmes-et-equipements-prioritaires-de-recherchepepr/propsy-psychiatrie-de-precision/ [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.